Medical technology company Hologic, Inc. (NASDAQ:HOLX) reported mixed fiscal first quarter results and provided weaker-than-expected guidance for the current quarter, sending shares down 3.4% in after-hours trading Wednesday.
For Q1 2025, Hologic posted adjusted earnings per share of $1.03, beating analyst estimates of $1.01. Revenue came in at $1.02 billion, slightly below the consensus forecast of $1.03 billion but up 0.9% YoY.
However, the company's outlook for Q2 fell short of expectations. Hologic forecast Q2 adjusted EPS of $1.00-$1.03, below the $1.04 analysts were projecting. Q2 revenue guidance of $995 million to $1.005 billion also missed the $1.033 billion consensus estimate.
"Our financial results for the first quarter of 2025 were consistent with our guidance overall," said Stephen P. MacMillan, Hologic's Chairman, President and CEO. " Total (EPA:TTEF) revenue finished in line with our guidance on a constant currency basis, and improved profitability helped us post non-GAAP earnings per share at the high end of our range."
For the full fiscal year 2025, Hologic lowered its revenue guidance to $4.05-$4.1 billion from its previous outlook of $4.15-$4.2 billion, citing currency headwinds and weakness in breast health capital sales. However, the company maintained its full-year adjusted EPS forecast of $4.25-$4.35.
Diagnostics revenue grew 5.1% to $470.6 million in Q1, while Breast Health revenue declined 2.3% to $369.1 million. Surgical revenue increased 2.5% to $166.3 million.
The company repurchased 6.8 million shares for $517 million during the quarter. Hologic ended Q1 with $1.78 billion in cash and cash equivalents.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.